|Videos|November 17, 2021
Dr. Ginsberg urges clinicians to consider onabotulinumtoxinA for OAB and urinary incontinence
Author(s)Urology Times staff
“Men do well and they don't have a really high risk of outcomes that we don't want them to have and that patients don't want to have, which is really the need to catheterize,” says David A. Ginsberg, MD.
Advertisement
In this video, David A. Ginsberg, MD, discusses the takeaways of the study, “Long-term, repeat treatments with onabotulinumtoxinA are well tolerated in male and female patients with overactive bladder and urinary incontinence: a pooled analysis of five clinical trials,” presented at the 2021 International Continence Society Meeting. Ginsberg is a professor of clinical oncology in the Health Sciences Campus at the University of Southern California, Los Angeles.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
